Literature DB >> 3756770

The long-term effect of cisplatin on renal function.

P Fjeldborg, J Sørensen, P E Helkjaer.   

Abstract

The long-term effect of cisplatin on renal function was studied in a follow-up investigation, 16 to 52 months after chemotherapy in 22 patients with disseminated nonseminomatous testicular cancer. The median cumulated cisplatin dose was 452 mg/m2 (range, 275-650 mg/m2). Prehydration with isotonic saline secured diuresis above 100 ml/hour. GFR (glomerular filtration rate: 51Cr-EDTA clearance) fell by 12.5% (median, P less than 0.01) compared with the pretreatment level. Effective renal plasma flow (125I-hippuran clearance) was estimated to be likewise reduced. The serum creatinine level rose 8 mumol/1 (median, P less than 0.05) during the treatment period with no further rise afterwards. Serum magnesium and urinary excretion of beta-2-microglobulin were normal. The results indicate a moderate and permanent reduction in GFR with no signs of long-term tubular defects in patients treated with cisplatin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3756770     DOI: 10.1002/1097-0142(19861115)58:10<2214::aid-cncr2820581009>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Cisplatin-induced reductions in renal functional reserve uncovered by unilateral nephrectomy: an experimental study in the pig.

Authors:  M E Robbins; D Campling; E Whitehouse; J W Hopewell; A Michalowski
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser.

Authors:  G Milano; V Troger; A Courdi; X Fontana; P Chauvel; J L Lagrange
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.

Authors:  J T Hartmann; L M Fels; S Knop; H Stolt; L Kanz; C Bokemeyer
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

6.  Cisplatin-associated anemia: an erythropoietin deficiency syndrome.

Authors:  P A Wood; W J Hrushesky
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Anticancer Chemotherapy and it's Anaesthetic Implications (Current Concepts).

Authors:  R P Gehdoo
Journal:  Indian J Anaesth       Date:  2009-02

8.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 9.  Long-term complications of chemotherapy for germ cell tumours.

Authors:  Uzair B Chaudhary; Jason R Haldas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Long-term studies of cisplatin-induced reductions in porcine renal functional reserve.

Authors:  M E Robbins; T B Bywaters; R S Jaenke; J W Hopewell; L M Matheson; P Tothill; E Whitehouse
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.